Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators

Dysregulation of RNA splicing by spliceosome mutations or in cancer genes is increasingly recognized as a hallmark of cancer. Small molecule splicing modulators have been introduced into clinical trials to treat solid tumors or leukemia bearing recurrent spliceosome mutations. Nevertheless, further...

Descripción completa

Detalles Bibliográficos
Autores principales: Aird, Daniel, Teng, Teng, Huang, Chia-Ling, Pazolli, Ermira, Banka, Deepti, Cheung-Ong, Kahlin, Eifert, Cheryl, Furman, Craig, Wu, Zhenhua Jeremy, Seiler, Michael, Buonamici, Silvia, Fekkes, Peter, Karr, Craig, Palacino, James, Park, Eunice, Smith, Peter G., Yu, Lihua, Mizui, Yoshiharu, Warmuth, Markus, Chicas, Agustin, Corson, Laura, Zhu, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329755/
https://www.ncbi.nlm.nih.gov/pubmed/30635584
http://dx.doi.org/10.1038/s41467-018-08150-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329755/
https://www.ncbi.nlm.nih.gov/pubmed/30635584
http://dx.doi.org/10.1038/s41467-018-08150-5

Ejemplares similares